Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Pharmaceutical Companies, Biotech Companies, Others), By End-User, By Region, And By Segment Forecasts, 2025-2034
Segmentation Of Investigational New Drug CDMO Market
By Product-
- Small Molecule
- Large Molecule
By Service-
- Contract Development
- Small Molecule
- Bioanalysis and DMPK studies
- Toxicology Testing
- Pathology and safety pharmacology studies
- Drug substance synthetic route development
- Drug substance process development
- Form selection crystallization process development
- Scale-up of drug substance
- Preformulation
- Preclinical formulation selection
- First in Man Formulation/Process Development
- Analytical method development/validation
- Release testing of drug substance and drug product
- Work up Purification Steps
- Telescoping & Process Refining
- Initial Optimization
- Formal stability of drug substance and drug product
- Large Molecule
- Cell Line development
- Process Development
- Upstream
- Microbial
- Mammalian
- Others
- Downstream
- MABs
- Recombinant proteins
- Others
- Upstream
- Small Molecule
- Contract Manufacturing
- Small Molecule
- Oral Solids
- Liquid and Semi-solids
- Injectables
- Others
- Large Molecule
- MABs
- Recombinant proteins
- Others
- Small Molecule
By End-Users-
- Pharmaceutical Companies
- Biotech Companies
- Others (Government, Research Institutes, Academic Institutes, Etc.)
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Investigational New Drug CDMO Market Snapshot
Chapter 4. Global Investigational New Drug CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product Type:
5.2.1. Percutaneous Endovascular Aneurysm Repair (EVAR)
5.2.2. Fenestrated EVAR
5.2.3. Aortic Stents Biodegradable Stents
5.2.4. Self- Expanding Nitinol Stents
5.2.5. Thoracic Aortic Aneurysm Grafts
5.2.6. Other Devices
Chapter 6. Market Segmentation 2: by Service Estimates & Trend Analysis
6.1. by Service & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service:
6.2.1. Contract Development
6.2.1.1. Small Molecule
6.2.1.1.1. Bioanalysis and DMPK studies
6.2.1.1.2. Toxicology Testing
6.2.1.1.3. Pathology and safety pharmacology studies
6.2.1.1.4. Drug substance synthetic route development
6.2.1.1.5. Drug substance process development
6.2.1.1.6. Form selection crystallization process development
6.2.1.1.7. Scale-up of drug substance
6.2.1.1.8. Preformulation
6.2.1.1.9. Preclinical formulation selection
6.2.1.1.10. First in Man Formulation/Process Development
6.2.1.1.11. Analytical method development/validation
6.2.1.1.12. Release testing of drug substance and drug product
6.2.1.1.13. Work up Purification Steps
6.2.1.1.14. Telescoping & Process Refining
6.2.1.1.15. Initial Optimization
6.2.1.1.16. Formal stability of drug substance and drug product
6.2.1.2. Large Molecule
6.2.1.2.1. Cell Line development
6.2.1.2.2. Process Development
6.2.1.2.2.1. Upstream
6.2.1.2.2.1.1. Microbial
6.2.1.2.2.1.2. Mammalian
6.2.1.2.2.1.3. Others
6.2.1.2.2.2. Downstream
6.2.1.2.2.2.1. MABs
6.2.1.2.2.2.2. Recombinant proteins
6.2.1.2.2.2.3. Others
6.2.2. Contract Manufacturing
6.2.2.1. Small Molecule
6.2.2.1.1. Oral Solids
6.2.2.1.2. Liquid and Semi-solids
6.2.2.1.3. Injectables
6.2.2.1.4. Others
6.2.2.2. Large Molecule
6.2.2.2.1. MABs
6.2.2.2.2. Recombinant proteins
6.2.2.2.3. Others
Chapter 7. Market Segmentation 3: by End-user Estimates & Trend Analysis
7.1. by End-user & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user:
7.2.1. Pharmaceutical Companies
7.2.2. Biotech Companies
7.2.3. Others (Government, Research Institutes, Academic Institutes, Etc.)
Chapter 8. Investigational New Drug CDMO Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.1.2. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2021-2034
8.1.3. North America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.1.4. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.2.2. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.2.3. Europe Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.2.4. Europe Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.3.2. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.3.3. Asia-Pacific Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.3.4. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.4.2. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.4.3. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.4.4. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.5.2. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.5.3. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.5.4. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Covance Inc.
9.2.2. Charles River Laboratories Inc.
9.2.3. Cambrex Corporation
9.2.4. IQVIA Holdings Inc.
9.2.5. Syneos Health
9.2.6. Lonza
9.2.7. Catalent
9.2.8. Recipharm AB
9.2.9. Siegfried Holding AG
9.2.10. Thermo Fisher Scientific Inc.
9.2.11. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Investigational New Drug CDMO Market Size is valued at USD 5.3 Billion in 2024 and is predicted to reach USD 9.6 Billion by 2034
Investigational New Drug CDMO Market is expected to grow at a 6.2% CAGR during the forecast period for 2025-2034
Lonza; Catalent; Recipharm AB; Siegfried Holding AG; Thermo Fisher Scientific Inc.; Covance Inc.; Charles River Laboratories; Cambrex Corporation; IQV
Product, Service and End-User are the key segments of the Investigational New Drug CDMO Market.
North America region is leading the Investigational New Drug CDMO Market.